Moderna, Inc. (MRNA): Price and Financial Metrics


Moderna, Inc. (MRNA)

Today's Latest Price: $70.55 USD

1.08 (1.55%)

Updated Sep 28 6:55pm

Add MRNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

MRNA Stock Summary

  • With a one year PEG ratio of 0.19, Moderna Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.35% of US stocks.
  • MRNA's went public 1.81 years ago, making it older than just 3.13% of listed US stocks we're tracking.
  • MRNA's price/sales ratio is 263.02; that's higher than the P/S ratio of 98.38% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Moderna Inc, a group of peers worth examining would be BNTX, ARGX, BGNE, DNLI, and FATE.
  • MRNA's SEC filings can be seen here. And to visit Moderna Inc's official web site, go to www.modernatx.com.
MRNA Daily Price Range
MRNA 52-Week Price Range

MRNA Stock Price Chart Technical Analysis Charts


MRNA Price/Volume Stats

Current price $70.55 52-week high $95.21
Prev. close $69.47 52-week low $13.53
Day low $69.10 Volume 7,337,300
Day high $71.50 Avg. volume 17,723,109
50-day MA $69.75 Dividend yield N/A
200-day MA $47.23 Market Cap 27.84B

Moderna, Inc. (MRNA) Company Bio


Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA


MRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

MRNA Latest Social Stream


Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Moderna (MRNA): Why This Bear Still Growls

It's been a couple of week now since SVB Leerink analyst Mani Foroohar cited worries about increased competition in the CVOID-19 vaccine race (200 vaccines in process, dozens in clinical trials), and mRNA-1273 lost "lead in clinical development" in deciding to downgrade Moderna (MRNA) stock to "underperform." A couple of weeks later... he's still not optimistic.Foroohar explains that mRNA-1273 still appears like it will prove to be an effective vaccine against coronavirus. The FDA is looking for vaccines to prove 50% "vaccine efficacy" at a minimum before approving them for Emergency Use Authorization (EUA). mRNA-1273 looks likely to clear that bar easily, with efficacy percentages trending to exceed 60%, and perhaps rise as high as 75% or better &q...

Yahoo | September 25, 2020

Why Covid-19 Vaccine Prices May Be Unexpectedly Low

If the vaccines now in final clinical trials against the coronavirus prove effective and safe, there should be plenty to go around.

Yahoo | September 25, 2020

Speculate on Inovio and Covid-19 Vaccine Developers

After bottoming at $10 earlier this month, investor interest soared in the last week for Inovio Pharmaceuticals (NASDAQ:INO). The company posted a corporate overview on its DNA medicines, increasing buying volume in INO stock.Source: Ascannio / Shutterstock.com What did Inovio say about its DNA Medicines?In Inovio's investor presentation, the company highlighted its proprietary smart device delivering plasmids. Already, it demonstrated a safe and robust immune response in more than 2,000 patients.InvestorPlace - Stock Market News, Stock Advice & Trading Tips DNA Medicine Lifts INO StockThe main DNA vaccines highlighted (slide 3) include the INO-4800, a Covid-19 vaccine. This vaccine showed long-term protection against live viruses in non-hospitalized patients 13-weeks after vaccinat...

Yahoo | September 25, 2020

COVID-19 trials enter late stages, here's when you should expect a vaccine

Yahoo Finance's Anjalee Khemlani joins the On the Move panel to break down the timeline for a COVID-19 vaccine as companies enter late stage trials.

Yahoo | September 25, 2020

U.S. nears 7M coronavirus cases, big pharmaceutical companies race for a vaccine

The U.S. is inching closer to hitting 7 million coronavirus cases as Midwest states like Wisconsin, Montana and South Dakota see an uptick. This comes as big pharmaceutical companies race to find a vaccine. Yahoo Finance's Anjalee Khemlani joins The First Trade with Alexis Christoforous and Brian Sozzi to discuss that and what pharmaceutical companies are close to reaching final stages of coronavirus vaccine trials.

Yahoo | September 25, 2020

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo 4.53%
3-mo 14.55%
6-mo 112.50%
1-year 343.15%
3-year N/A
5-year N/A
YTD 260.69%
2019 28.09%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6515 seconds.